Latest news - Page 5 of 9 - Explicyte Immuno-Oncology

digital spatial profiling DSP services tumor specimens biopsies

By charles_lbs4 May 20225 March 2025

Digital Spatial Profiling to reveal mechanisms of response to cancer immunotherapies

In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.

By charles_lbs29 March 20225 March 2025

We’ll be there! Meet Explicyte at AACR event in New Orleans

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there!

biomarker testing services immuno-oncology CRO

By charles_lbs24 March 20225 March 2025

Strenghten your immuno-oncology research with our complete digital pathology capacities

Drawing on our expertise in IHC and IHF assays, we have developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets.

By charles_lbs10 March 20225 March 2025

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement.

By charles_lbs22 February 20225 March 2025

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer

Discover our latest study, titled Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

By charles_lbs31 January 20225 March 2025

Targeting tryptophan catabolism in the era of cancer immunotherapy: challenges and perspectives

Discover our latest article, published in Frontiers in Immunology.

By charles_lbs27 January 20225 March 2025

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5).

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

By charles_lbs5 January 20225 March 2025

Our latest REGOMUNE study is just published!

Here is our latest publication, titled Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

By charles_lbs29 December 20215 March 2025

Discover our latest TRAMUNE study

Here is our latest publication, titled Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE).

nanostring spatial transcriptomics CRO services Immuno-oncology markers

By charles_lbs22 November 20215 March 2025

Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC

Discover why there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets and how to achieve it.

By charles_lbs22 October 20215 March 2025

Spotlight on adenosine-mediated suppression of dendritic cell function

Our data illustrated here through DC differentiation and mixed leukocyte reaction assays show that adenosine-mediated suppression results in the generation of phenotypically and functionally dysregulated DCs, and that this process is relieved by adenosine receptor antagonists.